New insulin copycat tested in healthy people – no cure, just comparison
NCT ID NCT05539872
First seen Mar 07, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tested whether a new rapid-acting insulin (I004) works the same as the approved insulin NovoLog. Sixty-nine healthy adults received single doses of both insulins in a blinded, crossover design. The goal was to measure how the body absorbs and responds to each insulin, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amphastar Study Site
Chula Vista, California, 91911, United States
Conditions
Explore the condition pages connected to this study.